About Valneva
Valneva is a company based in Lyon (France) founded in 1999.. Valneva has raised $113.55 million across 12 funding rounds from investors including Pfizer, European Investment Bank and Bpifrance. The company has 713 employees as of December 31, 2024. Valneva offers products and services including IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine). Valneva operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Lyon, France
- Employees 713 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Valneva Se
-
Annual Revenue
$176.18 M (USD)10.32as on Dec 31, 2024
-
Net Profit
$-12.73 M (USD)87.93as on Dec 31, 2024
-
EBITDA
$-82.04 M (USD)8.71as on Dec 31, 2024
-
Total Equity Funding
$113.55 M (USD)
in 12 rounds
-
Latest Funding Round
$102 M (USD), Post-IPO
Oct 05, 2022
-
Investors
Pfizer
& 7 more
-
Employee Count
713
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Valneva
Valneva is a publicly listed company on the EURONEXT with ticker symbol VLA in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Valneva
Valneva offers a comprehensive portfolio of products and services, including IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Prophylactic vaccine to prevent chikungunya infection.
Vaccine for Lyme disease prevention and protection.
Vaccine targeting Shigella infections.
Prophylactic vaccine against Zika virus.
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Software Development Team
17 people
Senior Team
11 people
Finance and Accounting
10 people
Head Team
10 people
Product Management Team
9 people
Human Resources and Administration
9 people
Operations Team
8 people
Unlock access to complete
Funding Insights of Valneva
Valneva has successfully raised a total of $113.55M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $102 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $102.0M
-
First Round
First Round
(17 Mar 2008)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2022 | Amount | Post-IPO - Valneva | Valuation |
investors |
|
| Jun, 2022 | Amount | Post-IPO - Valneva | Valuation |
investors |
|
| Feb, 2022 | Amount | Grant - Valneva | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Valneva
Valneva has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, European Investment Bank and Bpifrance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location | |
|
Healthcare investments are targeted by this private equity firm.
|
Founded Year | Domain | Location | |
|
Private equity investments in healthcare companies are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Valneva
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Valneva
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Valneva Comparisons
Competitors of Valneva
Valneva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Valneva
Frequently Asked Questions about Valneva
When was Valneva founded?
Valneva was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Where is Valneva located?
Valneva is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is Valneva a funded company?
Valneva is a funded company, having raised a total of $113.55M across 12 funding rounds to date.
How many employees does Valneva have?
As of Dec 31, 2024, the latest employee count at Valneva is 713.
What is the annual revenue of Valneva?
Annual revenue of Valneva is $176.18M as on Dec 31, 2024.
What does Valneva do?
Valneva was founded in 1999 and is headquartered in Lyon, France. Operations are centered in the biotechnology sector, where prophylactic vaccines against infectious diseases are developed. Key candidates include VLA1553, a live-attenuated single-dose vaccine for chikungunya virus, alongside VLA15 targeting Lyme disease, VLA84 for Clostridium difficile prevention, and VLA1601 for Zika virus protection. Research and development efforts are directed toward addressing unmet needs in global health.
Who are the top competitors of Valneva?
Valneva's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
What products or services does Valneva offer?
Valneva offers IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine).
Is Valneva publicly traded?
Yes, Valneva is publicly traded on EURONEXT under the ticker symbol VLA.
Who are Valneva's investors?
Valneva has 8 investors. Key investors include Pfizer, European Investment Bank, Bpifrance, CEPI, and MVM Partners.
What is Valneva's ticker symbol?
The ticker symbol of Valneva is VLA on EURONEXT.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.